Unmet Needs in Advanced or Metastatic TRK Fusion+ Thyroid Cancer

Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.

Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.

According to Cabanillas, more options for RET, ALK, and BRAF mutations exist. TRK mutations are another rare fusion requiring a TRK inhibitor. Additionally, there are limitations on the 2 currently approved therapies sorafenib (Nexavar) and lenvatinib (Lenvima). For some patients, these therapies are too toxic, according to Cabanillas.

For patients who have a predisposition for bleeding, especially bleeding from the tumor VEGF inhibitors may be too unsafe as the increase bleeding risk. There is a need for more tolerable therapies for this patient population.